Double-blind within-subject crossover neuroimaging study (Biol Psychiatry Cogn Neurosci Neuroimaging 2022 Mar; Kotoula V, Stringaris A, Mackes N, Mazibuko N et al.; PMID 34126264; DOI 10.1016/j.bpsc.2021.05.009). Participants: n=18 adults (21–65 yr) in remission from DSM-IV MDD; antidepressant-free; no current symptoms; Inventory of Depressive Symptomatology score <32 and documented prior nonresponse. Crossover: single IV ketamine (0.5 mg/kg over 40 min) and saline placebo on separate sessions ≥7 days apart; fMRI (3T, MID task, 96 trials) acquired 2 h post-infusion. Blood samples at pre-infusion, immediately post-infusion and 2 h post-infusion for ketamine, norketamine, and HNK metabolites. Primary ROIs: bilateral ventral striatum, dorsal striatum, VTA, amygdala, insula, sgACC. CT.gov: 0 hits; PubMed DataBankList: empty; no registration number in methods.
Single 40-minute steady state intravenous infusion of ketamine (0.5 mg/kg)
40min steady state infusion
Single 40-minute steady state intravenous infusion of 0.9% saline solution
0.9% saline solution administered via 40min steady state infusion